Doctronic

About Doctronic

Doctronic is a New York-based healthcare technology company developing an AI-powered platform for real-time medical information and patient-doctor communication. Founded in 2023 by Dr. Adam Oskowitz and Matt Pavelle, the company aims to address the challenge of timely access to quality healthcare. The founding duo combines deep clinical and technical expertise; Dr. Oskowitz is a practicing vascular surgeon with over two decades of experience, and Pavelle is a seasoned technologist and repeat founder. Pavelle's personal experience with delayed diagnoses inspired the idea of using AI for triage, while Dr. Oskowitz brought the clinical rigor to ensure the platform's safety and effectiveness.

The company's core offering is a 24/7 AI health assistant that provides free, personalized health insights. Users can engage in a conversation with the AI to discuss symptoms and receive potential diagnoses, treatment plans, and clinically formatted documentation, like SOAP notes, to share with a provider. The platform's multi-agent AI system simulates an internal debate among specialized AI agents to refine conclusions before making a final recommendation. For users requiring further care, Doctronic provides seamless access to a national network of licensed physicians for video visits, which can be paid for with an insurance copay or a flat fee for the uninsured. The business model centers on these physician visits, while the initial AI consultation remains free. Doctronic also serves health systems, payers, and employers through co-branded digital health partnerships.

A significant milestone for Doctronic was becoming the first AI-native platform legally authorized to autonomously renew prescriptions in the United States, a capability launched in December 2025 under Utah's AI Learning Lab regulatory sandbox. This allows the system to handle prescription renewals for numerous chronic conditions, with built-in safeguards that escalate complex cases to human physicians. The company has demonstrated significant growth, reporting a 15x increase in annualized revenue to eight figures in less than six months and seeing over 300,000 unique weekly visitors. Doctronic has raised over $65 million in total funding, including a $40 million Series B round in March 2026 co-led by Abstract and Lightspeed Venture Partners. The company plans to use the capital to expand into pediatrics and forge deeper partnerships with hospitals, academic institutions, and payers.